ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1511

Lupus Nephritis and Response to Treatment in Latin America
Abstract Number: 1512

Association Between the Systemic Immune Inflammatory Index (Sll) and All-cause Mortality in Critically Ill Patients with Rheumatoid Arthritis
Abstract Number: 1513

Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20
Abstract Number: 1514

Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Abstract Number: 1515

Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
Abstract Number: 1516

Diagnostic Performance of Anti-ribosomal P Antibodies in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus with Diffuse Central Nervous System Manifestations. Experience in a Tertiary Center in Mexico
Abstract Number: 1517

Diagnostic Performance of Anti-dsDNA Antibodies in Pleural, Ascitic and Pericardial Fluid for Lupus Serositis: Experience of a Tertiary Center in Mexico
Abstract Number: 1518

Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Abstract Number: 1519

Incidence, Risk Factors, and Outcomes of Severe Lymphopenia in Systemic Lupus Erythematosus
Abstract Number: 1520

The Influence of Trauma on Features of Type 2 SLE
Abstract Number: 1521

Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Abstract Number: 1522

Impact of Thrombocytopenia on In-hospital Mortality and Healthcare Resource Utilization in Patients with Systemic Lupus Erythematosus: An Analysis of the National Inpatient Sample Database 2020
Abstract Number: 1523

Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020
Abstract Number: 1524

Thrombocytopenia and Systemic Lupus Erythematosus: A Meta-analysis of Observational Studies
Abstract Number: 1525

Early versus Late Lupus Nephritis: A Meta-analysis of Observational Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].